Prospera^™

For kidney transplant assessment

Covered by Medicare, Prospera is a transplant rejection assessment test that uses a simple blood draw to evaluate the risk of rejection of a transplanted kidney.

Through the use of advanced cell-free DNA technology, Prospera increases a provider’s ability to identify otherwise undetected rejection that might lead to kidney loss. Catching transplant rejection as soon as possible can help providers develop a treatment plan to best protect the donated kidney.

Setting a new standard through research

Best-in-class care depends on best-in-class assessment

Prospera is the most advanced cfDNA solution for assessing transplant rejection — reinforced by ongoing research efforts.

Sigdel et al Clinical Validation: Published in 2019

Conducted with the University of California, San Francisco
Largest biopsy-matched study conducted in renal transplantation assessing the use of cell-free DNA
The first to publish performance of cell-free DNA testing in subclinical, surveillance setting

View: Sigdel et al paper

ProActive Registry Study: Now Enrolling

Largest clinical utility study evaluating cell-free DNA; includes more than 3,000 kidney transplants studied for three years
Long-term assessment of high-risk recipients for up to 5 years post-transplantation
Personalized transplant management protocols using cell-free DNA data

Visit the ProActive Study
Read about ProActive Recruitment Milestone
View study

Research with the Molecular Microscope Diagnostic System (MMDX): Now Enrolling

Global, prospective multicenter study under the leadership of Dr. Philip Halloran
300 patients to be comprehensively evaluated with clinical information, cell-free DNA measures, biopsies, molecular microscope, evaluations, and donor-specific antibodies (DSA)
Integrated data analysis to better inform non-invasive and interventional management in kidney transplantation

View here

PEDAL Study: Now Enrolling

500 kidney transplant patients from 20 major US centers
Evaluation of how quantifying the absolute concentration of background cell-free DNA (cfDNA) may allow for a more precise and confident assessment of allograft rejection — especially in identifying patients at-risk of false-negative interpretations

CONCERT Study: To accelerate clearance for renal transplantation in molecular residual disease (MRD)-negative patients with a history of colorectal cancer
PARC Study: To understand how malignancies and cancer therapy affect background cell-free DNA levels in renal allograft patients
SIGNAL Study: To observe Signatera in patients with liver cancer to determine molecular residual disease (MRD) rates before and after liver transplant

MOTR Study: Now Enrolling

Study to determine utility of Prospera in multiple organ transplant patients
Evaluate 400 kidney-liver, kidney-pancreas and kidney-heart patients

Talk to us

Prospera™